$HOTH
Hoth Therapeutics Inc

2024 Q3 Form 10-Q Financial Statement

#000121390024067131 Filed on August 09, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2 2023 Q2
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.080M $1.010M
YoY Change 6.85% 325.13%
% of Gross Profit
Research & Development $566.3K $641.0K
YoY Change -11.64% -34.0%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $1.646M $1.709M
YoY Change -3.67% -25.7%
Operating Profit -$1.646M -$1.709M
YoY Change -3.67% -25.7%
Interest Expense $13.37K -$164.4K
YoY Change -108.13% -56.48%
% of Operating Profit
Other Income/Expense, Net $13.37K -$164.4K
YoY Change -108.13% -56.51%
Pretax Income -$1.632M -$1.873M
YoY Change -12.84% -30.05%
Income Tax
% Of Pretax Income
Net Earnings -$1.632M -$1.873M
YoY Change -12.84% -30.05%
Net Earnings / Revenue
Basic Earnings Per Share -$0.24 -$0.57
Diluted Earnings Per Share -$0.24 -$0.57
COMMON SHARES
Basic Shares Outstanding 6.904M shares 4.889M shares 3.302M shares
Diluted Shares Outstanding 6.876M shares 3.302M shares

Balance Sheet

Concept 2024 Q3 2024 Q2 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $9.655M $11.57M
YoY Change -16.55% -0.45%
Cash & Equivalents $9.655M $11.54M
Short-Term Investments $24.57K
Other Short-Term Assets $299.7K $314.9K
YoY Change -4.82% 64.7%
Inventory
Prepaid Expenses $314.9K
Receivables
Other Receivables
Total Short-Term Assets $9.955M $11.88M
YoY Change -16.24% 0.18%
LONG-TERM ASSETS
Property, Plant & Equipment $41.10K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $36.82K $33.00K
YoY Change 11.58% -91.48%
Other Assets
YoY Change
Total Long-Term Assets $77.92K $33.00K
YoY Change 136.13% -91.48%
TOTAL ASSETS
Total Short-Term Assets $9.955M $11.88M
Total Long-Term Assets $77.92K $33.00K
Total Assets $10.03M $11.92M
YoY Change -15.82% -2.72%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $333.3K $520.7K
YoY Change -35.98% -23.37%
Accrued Expenses $317.4K $1.162M
YoY Change -72.68% 2258.26%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $680.8K $1.716M
YoY Change -60.33% 127.7%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $11.04K $250.0K
YoY Change -95.58% -9.09%
Total Long-Term Liabilities $11.04K $250.0K
YoY Change -95.58% -9.09%
TOTAL LIABILITIES
Total Short-Term Liabilities $680.8K $1.716M
Total Long-Term Liabilities $11.04K $250.0K
Total Liabilities $691.9K $1.966M
YoY Change -64.81% 91.13%
SHAREHOLDERS EQUITY
Retained Earnings -$56.60M -$49.16M
YoY Change 15.14% 26.12%
Common Stock $536.00 $330.00
YoY Change 62.42% -89.75%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $9.341M $9.951M
YoY Change
Total Liabilities & Shareholders Equity $10.03M $11.92M
YoY Change -15.82% -2.72%

Cashflow Statement

Concept 2024 Q3 2024 Q2 2023 Q2
OPERATING ACTIVITIES
Net Income -$1.632M -$1.873M
YoY Change -12.84% -30.05%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$1.592M -$1.450M
YoY Change 9.8% -34.78%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change -100.0%
Cash From Investing Activities $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.682M 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -1.592M -1.450M
Cash From Investing Activities 0.000
Cash From Financing Activities 3.682M 0.000
Net Change In Cash 2.091M -1.450M
YoY Change -244.21% -129.31%
FREE CASH FLOW
Cash From Operating Activities -$1.592M -$1.450M
Capital Expenditures $0.00
Free Cash Flow -$1.450M
YoY Change -33.23%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.57
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.65
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2894732 shares
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38803
dei Entity Registrant Name
EntityRegistrantName
Hoth Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-1553794
dei Entity Address Address Line1
EntityAddressAddressLine1
590 Madison Ave
dei Entity Address Address Line2
EntityAddressAddressLine2
21st Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
New York
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10022
dei City Area Code
CityAreaCode
(646)
dei Local Phone Number
LocalPhoneNumber
756-2997
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value
dei Trading Symbol
TradingSymbol
HOTH
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
6903804 shares
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9654837 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9292352 usd
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
299708 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
135361 usd
CY2024Q2 us-gaap Assets Current
AssetsCurrent
9954545 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
9427713 usd
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
41104 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
55165 usd
CY2024Q2 us-gaap Investments In Affiliates Subsidiaries Associates And Joint Ventures
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
36819 usd
CY2023Q4 us-gaap Investments In Affiliates Subsidiaries Associates And Joint Ventures
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
37400 usd
CY2024Q2 us-gaap Assets Noncurrent
AssetsNoncurrent
77923 usd
CY2023Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
92565 usd
CY2024Q2 us-gaap Assets
Assets
10032468 usd
CY2023Q4 us-gaap Assets
Assets
9520278 usd
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
333346 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
35592 usd
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
317410 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
614226 usd
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
30060 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
28839 usd
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
680816 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
678657 usd
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
11044 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
26326 usd
CY2024Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
11044 usd
CY2023Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
26326 usd
CY2024Q2 us-gaap Liabilities
Liabilities
691860 usd
CY2023Q4 us-gaap Liabilities
Liabilities
704983 usd
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2024Q2 hoth Preferred Stock Shares Undesignated
PreferredStockSharesUndesignated
3000000 shares
CY2023Q4 hoth Preferred Stock Shares Undesignated
PreferredStockSharesUndesignated
3000000 shares
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5358804 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5358804 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4348129 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4348129 shares
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
536 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
435 usd
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
65934709 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
61732106 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-56617763 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-52944506 usd
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
23126 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
27260 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
9340608 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
8815295 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
10032468 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
9520278 usd
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
566335 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
652202 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1032231 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1591080 usd
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1079504 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1056427 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2667766 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2310366 usd
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
1645839 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
1708629 usd
us-gaap Operating Expenses
OperatingExpenses
3699997 usd
us-gaap Operating Expenses
OperatingExpenses
3901446 usd
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1645839 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1708629 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-3699997 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-3901446 usd
CY2023Q2 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-165950 usd
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-184753 usd
us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
-581 usd
CY2024Q2 us-gaap Investment Income Dividend
InvestmentIncomeDividend
13365 usd
CY2023Q2 us-gaap Investment Income Dividend
InvestmentIncomeDividend
1548 usd
us-gaap Investment Income Dividend
InvestmentIncomeDividend
27321 usd
us-gaap Investment Income Dividend
InvestmentIncomeDividend
29661 usd
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
13365 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-164402 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
26740 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-155092 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-1632474 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1873031 usd
us-gaap Net Income Loss
NetIncomeLoss
-3673257 usd
us-gaap Net Income Loss
NetIncomeLoss
-4056538 usd
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.24
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.57
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.65
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.4
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6876331 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3302113 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5637621 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2894732 shares
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-1632474 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1873031 usd
us-gaap Net Income Loss
NetIncomeLoss
-3673257 usd
us-gaap Net Income Loss
NetIncomeLoss
-4056538 usd
CY2024Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
1634 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-51088 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-4134 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-45718 usd
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1630840 usd
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1924119 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3677391 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4102256 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
8815295 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
513350 usd
CY2024Q1 hoth Adjustmentsto Additional Paidin Capital Stock Issued Ownshare Lending Arrangement Issuance Costs
AdjustmentstoAdditionalPaidinCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts
550500 usd
CY2024Q1 us-gaap Cumulative Translation Adjustment Net Of Tax Period Increase Decrease
CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease
-5768 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-2040783 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
7832594 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7054 usd
CY2024Q2 hoth Stock Issued During Period Value Common Shares Issued And Issuable For Exercise Of Warrants
StockIssuedDuringPeriodValueCommonSharesIssuedAndIssuableForExerciseOfWarrants
3682300 usd
CY2024Q2 hoth Adjustmentsto Additional Paidin Capital Stock Issued Ownshare Lending Arrangement Issuance Costs
AdjustmentstoAdditionalPaidinCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts
-550500 usd
CY2024Q2 us-gaap Cumulative Translation Adjustment Net Of Tax Period Increase Decrease
CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease
1634 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-1632474 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
9340608 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
5121650 usd
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1860 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10630 usd
CY2023Q1 hoth Stock Issued During Period Value Common Stock And Warrants Issued In Private Placement Net Of Offering Costs
StockIssuedDuringPeriodValueCommonStockAndWarrantsIssuedInPrivatePlacementNetOfOfferingCosts
8909530 usd
CY2023Q1 us-gaap Cumulative Translation Adjustment Net Of Tax Period Increase Decrease
CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease
5370 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2183507 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
11865533 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9748 usd
CY2023Q2 us-gaap Cumulative Translation Adjustment Net Of Tax Period Increase Decrease
CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease
-51088 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1873031 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
9951162 usd
us-gaap Net Income Loss
NetIncomeLoss
-3673257 usd
us-gaap Net Income Loss
NetIncomeLoss
-4056538 usd
hoth Research And Developmentlicenses Acquired Expensed
ResearchAndDevelopmentlicensesAcquiredExpensed
8750 usd
us-gaap Share Based Compensation
ShareBasedCompensation
520404 usd
us-gaap Share Based Compensation
ShareBasedCompensation
20378 usd
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-184753 usd
us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
-581 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
164347 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
227391 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
938 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
330933 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3315681 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3739115 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
8909530 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
3682300 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
1860 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3682300 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8911390 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
366619 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
5172275 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-4134 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-56084 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9292352 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6428611 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9654837 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11544802 usd
hoth Increase In Deferred Offering Cost And Additional Paidin Capital
IncreaseInDeferredOfferingCostAndAdditionalPaidinCapital
550500 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-56600000 usd
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9700000 usd
CY2024Q2 hoth Warrants Purchase To Shares
WarrantsPurchaseToShares
2500000 shares
CY2024Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
955000 shares
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Reclassifications</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain line items on the unaudited condensed consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2023 have been reclassified to conform to the current period presentation. For the three months ended June 30, 2023, research and development - licenses acquired (including stock-based compensation) of $11,243 was reclassified to research and development expense, and compensation and related expenses (including stock-based compensation) of $518,476, professional fees (including stock-based compensation) of $483,883, rent of $7,897, and other general and administrative expense of $46,171 were consolidated into one general and administrative expenses line item. For the six months ended June 30, 2023, research and development - licenses acquired (including stock-based compensation) of $59,276 was reclassified to research and development expenses, and compensation and related expenses (including stock-based compensation) of $814,040, professional fees (including stock-based compensation) of $1,100,258, rent of $23,017, and other general and administrative expense of $373,051 were consolidated into one general and administrative expenses line item. These reclassifications did not change the Company’s reported net loss or comprehensive loss for the three and six months ended June 30, 2023.</p>
CY2023Q2 us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
11243 usd
CY2023Q2 hoth Compensation And Related Expenses
CompensationAndRelatedExpenses
518476 usd
CY2023Q2 us-gaap Professional Fees
ProfessionalFees
483883 usd
CY2023Q2 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
7897 usd
CY2023Q2 us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
46171 usd
us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
59276 usd
hoth Compensation And Related Expenses
CompensationAndRelatedExpenses
814040 usd
us-gaap Professional Fees
ProfessionalFees
1100258 usd
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
23017 usd
us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
373051 usd
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1235000000 usd
CY2024Q2 hoth Non Convertible Debt
NonConvertibleDebt
1000000000 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Use of estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. The most significant estimates in the Company’s unaudited condensed consolidated financial statements relate to stock-based compensation, the valuation of modified warrants, and the valuation allowance of deferred tax assets resulting from net operating losses. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations may be affected. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9654837 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9292352 usd
CY2024Q2 us-gaap Cash Held In Foreign Currency
CashHeldInForeignCurrency
100000 usd
CY2023Q4 us-gaap Cash Held In Foreign Currency
CashHeldInForeignCurrency
100000 usd
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Concentrations of credit risk and off-balance sheet risk</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has significant cash balances at financial institutions which, throughout the year, regularly exceed the federally insured limit of $250,000. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company’s financial condition, results of operations, and cash flows.</p>
CY2024Q2 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5830903 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3110875 shares
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.05 pure
hoth Schedule Of Research And Development Expenses For Licenses Acquired
ScheduleOfResearchAndDevelopmentExpensesForLicensesAcquired
The following summarizes the Company’s research and development expenses for licenses acquired (including stock-based compensation) during the three and six months ended June 30, 2024 and 2023:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Three Months Ended<br/> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Six Months Ended<br/> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">The George Washington University</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">8,597</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">10,618</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">9,847</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">51,776</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">North Carolina State University</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,563</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,125</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Virginia Commonwealth University</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,250</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt">University of Cincinnati</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">417</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">625</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">417</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,250</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">10,577</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">11,243</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">13,389</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">59,276</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2024Q2 us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
10577 usd
CY2023Q2 us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
11243 usd
us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
13389 usd
us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
59276 usd
CY2024Q2 us-gaap Investments In Affiliates Subsidiaries Associates And Joint Ventures Fair Value Disclosure
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure
36819 usd
CY2023Q2 us-gaap Investments In Affiliates Subsidiaries Associates And Joint Ventures Fair Value Disclosure
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure
37400 usd
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2024Q2 hoth Preferred Stock Shares Undesignated
PreferredStockSharesUndesignated
3000000 shares
CY2023Q4 hoth Preferred Stock Shares Undesignated
PreferredStockSharesUndesignated
3000000 shares
CY2022Q4 hoth Common Stock Warrants Price Per Share
CommonStockWarrantsPricePerShare
5
CY2022Q4 hoth Pre Funded Warrants Price Per Share
PreFundedWarrantsPricePerShare
0.001
CY2022Q4 us-gaap Sale Of Stock Consideration Received Per Transaction
SaleOfStockConsiderationReceivedPerTransaction
10000000 usd
CY2022Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
5
CY2023Q1 hoth Pre Funded Common Stock Warrants Sold
PreFundedCommonStockWarrantsSold
1860000 shares
CY2023Q1 hoth Net Proceeds To Company
NetProceedsToCompany
1860 usd
CY2023Q1 hoth Purchase Of Common Stock Warrants
PurchaseOfCommonStockWarrants
100000 shares
CY2024Q1 hoth Warrants Aggregate
WarrantsAggregate
2500000 shares
hoth Purchase Of Warrants Common Stock
PurchaseOfWarrantsCommonStock
3750000 shares
CY2024Q2 us-gaap Warrants And Rights Outstanding Maturity Date
WarrantsAndRightsOutstandingMaturityDate
2028-07-03
CY2024Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.6775
CY2024Q2 hoth Warrant Exercise Shares
WarrantExerciseShares
2500000 shares
hoth Warrant Exercise Shares
WarrantExerciseShares
955000 shares
CY2024Q2 hoth Warrants Shares For Future Issuance
WarrantsSharesForFutureIssuance
1545000 shares
CY2024Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
4166800 usd
hoth Unrecognized Stockbased Compensation Expense
UnrecognizedStockbasedCompensationExpense
1213 usd
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
1.36
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
1.20 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0402 pure
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
169362 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
26.78
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
P8Y4M24D
us-gaap Stock Issued During Period Shares Employee Stock Ownership Plan
StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan
450000 shares
hoth Share Based Compensation Arrangements By Share Based Payment Award Options Weighted Average Exercise Price Employee Options Issued
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceEmployeeOptionsIssued
1.36
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
2000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
147
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
617362 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.86
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
P9Y1M6D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
617362 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
7.86
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P9Y1M6D
CY2024Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
0 usd
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7054 usd
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9748 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
520404 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
20378 usd
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7054 usd
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9748 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
520404 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
20378 usd
CY2024Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
5615 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
14232 usd
CY2024Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
5840 usd
CY2023Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
7897 usd
us-gaap Short Term Lease Cost
ShortTermLeaseCost
10493 usd
us-gaap Short Term Lease Cost
ShortTermLeaseCost
23017 usd
CY2024Q2 us-gaap Lease Cost
LeaseCost
11455 usd
CY2023Q2 us-gaap Lease Cost
LeaseCost
7897 usd
us-gaap Lease Cost
LeaseCost
24725 usd
us-gaap Lease Cost
LeaseCost
23017 usd
CY2024Q2 hoth Office Lease Rightofuse Asset
OfficeLeaseRightofuseAsset
59698 usd
CY2023Q4 hoth Office Lease Rightofuse Asset
OfficeLeaseRightofuseAsset
59698 usd
CY2024Q2 hoth Accumulated Amortization
AccumulatedAmortization
-18594 usd
CY2023Q4 hoth Accumulated Amortization
AccumulatedAmortization
-4533 usd
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
41104 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
55165 usd
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
30060 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
28839 usd
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
11044 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
26326 usd
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
41104 usd
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
55165 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
16392 usd
CY2024Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y
hoth Weighted Average Incremental Borrowing Rate
WeightedAverageIncrementalBorrowingRate
0.10 pure
CY2023 hoth Weighted Average Incremental Borrowing Rate
WeightedAverageIncrementalBorrowingRate
0.10 pure
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
32784 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
10928 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
43712 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
2608 usd
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
41104 usd
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q2 us-gaap Revenues
Revenues
usd
CY2023Q2 us-gaap Revenues
Revenues
usd
us-gaap Revenues
Revenues
usd
us-gaap Revenues
Revenues
usd
CY2024Q2 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
usd
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
usd
CY2024Q2 us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
usd
CY2023Q2 us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
usd
us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
usd
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.24
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.40
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3302113 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5637621 shares
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6876331 shares
CY2024Q1 hoth Stock Issued During Period Value Stock Options Exercised Of Prefunded Warrants
StockIssuedDuringPeriodValueStockOptionsExercisedOfPrefundedWarrants
usd
CY2024Q2 hoth Stock Issued During Period Value Stock Options Exercised Of Prefunded Warrants
StockIssuedDuringPeriodValueStockOptionsExercisedOfPrefundedWarrants
usd
hoth Research And Developmentlicenses Acquired Expensed
ResearchAndDevelopmentlicensesAcquiredExpensed
usd
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
usd
us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
usd
hoth Increase In Deferred Offering Cost And Additional Paidin Capital
IncreaseInDeferredOfferingCostAndAdditionalPaidinCapital
usd
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
pure
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
usd
hoth Share Based Compensation Arrangement By Share Based Payment Award Options Intrinsic Value Employee Options Issued
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueEmployeeOptionsIssued
usd
hoth Sharebased Compensation Arrangement By Sharebased Payment Award Options Weighted Average Remaining Contractual Lifein Years Employee Options Issued
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeinYearsEmployeeOptionsIssued
hoth Share Based Compensation Arrangement By Share Based Payment Award Options Intrinsic Value Expired
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueExpired
usd
hoth Sharebased Compensation Arrangement By Sharebased Payment Award Options Weighted Average Remaining Contractual Lifein Years Expired
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeinYearsExpired
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
usd
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
usd
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
usd
us-gaap Operating Lease Cost
OperatingLeaseCost
usd
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001711786

Files In Submission

Name View Source Status
0001213900-24-067131-index-headers.html Edgar Link pending
0001213900-24-067131-index.html Edgar Link pending
0001213900-24-067131.txt Edgar Link pending
0001213900-24-067131-xbrl.zip Edgar Link pending
ea0210289-10q_hoththerap.htm Edgar Link pending
ea021028901ex31-1_hoththerap.htm Edgar Link pending
ea021028901ex31-2_hoththerap.htm Edgar Link pending
ea021028901ex32-1_hoththerap.htm Edgar Link pending
ea021028901ex32-2_hoththerap.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
hoth-20240630.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
ea0210289-10q_hoththerap_htm.xml Edgar Link completed
hoth-20240630_cal.xml Edgar Link unprocessable
hoth-20240630_def.xml Edgar Link unprocessable
hoth-20240630_lab.xml Edgar Link unprocessable
hoth-20240630_pre.xml Edgar Link unprocessable
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable